Patents by Inventor Ester Fernandez-Salas

Ester Fernandez-Salas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Degradable clostridial toxins
    Patent number: 9279116
    Abstract: The specification discloses Clostridial toxins or Clostridial toxin chimeras comprising an inactivation cleavage site, polynucleotide molecules encoding such toxins or chimeras, compositions comprising such toxins or chimeras, and method of producing such toxins or chimeras.
    Type: Grant
    Filed: November 21, 2013
    Date of Patent: March 8, 2016
    Assignee: Allergan, Inc.
    Inventors: Lance E. Steward, Sanjiv Ghanshani, Ester Fernandez-Salas, Marcella A. Gilmore, Joseph Francis, Kei Roger Aoki
  • Immuno-based botulinum toxin serotype A activity assays
    Patent number: 9249216
    Abstract: The present specification discloses SNAP-25 compositions, methods of making ?-SNAP-25 antibodies that bind an epitope comprising a carboxyl-terminus at the P1 residue from the BoNT/A cleavage site scissile bond from a SNAP-25 cleavage product, ?-SNAP-25 antibodies that bind an epitope comprising a carboxyl-terminus at the P1 residue from the BoNT/A cleavage site scissile bond from a SNAP-25 cleavage product, methods of detecting BoNT/A activity, and methods of detecting neutralizing ?-BoNT/A antibodies.
    Type: Grant
    Filed: May 18, 2012
    Date of Patent: February 2, 2016
    Assignee: Allergan, Inc.
    Inventors: Ester Fernandez-Salas, Joanne Wang, Patton Garay, Lina S. Wong, D. Diane Hodges, Kei Roger Aoki
  • METHOD OF DETECTING CLEAVED SNAP25 IN TISSUE SAMPLES
    Publication number: 20160003824
    Abstract: Methods and compositions for detecting BoNT/A enzymatic activity in tissues or a tissue sample are described herein. The invention encompasses antibodies that bind preferentially to BoNT/A cleaved SNAP25 and is able to preferentially detect BoNT/A cleaved SNAP25, as compared to intact (non-cleaved) SNAP25, in a tissue sample.
    Type: Application
    Filed: July 7, 2015
    Publication date: January 7, 2016
    Inventors: Ron S. Broide, Brian Cai, Ester Fernandez-Salas, Joseph Francis, Catherine Rheaume
  • FORMULATIONS OF BIOLOGICS FOR INTRAVESICAL INSTILLATION
    Publication number: 20150313973
    Abstract: Pharmaceutical formulations comprising a clostridial derivative and a permeabilizing agent for intravesical instillation are disclosed.
    Type: Application
    Filed: April 30, 2015
    Publication date: November 5, 2015
    Inventors: Eric A. Forssen, Patrick M. Hughes, David C. Rupp, Terrence Hunt, Gary Shimizu, Joseph Francis, Ron S. Broide, Ester Fernandez-Salas
  • IMMUNO-BASED RETARGETED ENDOPEPTIDASE ACTIVITY ASSAYS
    Publication number: 20150301050
    Abstract: The present specification discloses a retargeted endopeptidase pharmaceutical wherein the activity has been determined by the methods disclosed.
    Type: Application
    Filed: April 24, 2015
    Publication date: October 22, 2015
    Inventors: Joanne Wang, Hong Zhu, Dianne D. Hodges, Ester Fernandez-Salas
  • Degradable clostridial toxins
    Patent number: 8841111
    Abstract: The specification discloses Clostridial toxins or Clostridial toxin chimeras comprising an inactivation cleavage site, polynucleotide molecules encoding such toxins or chimeras, compositions comprising such toxins or chimeras, and method of producing such toxins or chimeras.
    Type: Grant
    Filed: March 18, 2013
    Date of Patent: September 23, 2014
    Assignee: Allergan, Inc.
    Inventors: Lance E. Steward, Sanjiv Ghanshani, Ester Fernandez-Salas, Marcella A. Gilmore, Joseph Francis, Kei Roger Aoki
  • Highly Sensitive Cell-Based Assay to Detect the Presence of Active Botulinum Neurotoxin Serotype-A
    Publication number: 20140248644
    Abstract: The present specification discloses methods for detecting extremely low amounts of botulinum neurotoxin serotype A in samples, including complex matrices like blood, plasma, and serum.
    Type: Application
    Filed: December 28, 2012
    Publication date: September 4, 2014
    Inventors: Joanne Wang, Anuradha Dixit, Kenton B. Abel, Swati Gupta, Ester Fernandez-Salas
  • Degradable Clostridial Toxins
    Publication number: 20140227740
    Abstract: The specification discloses Clostridial toxins or Clostridial toxin chimeras comprising an inactivation cleavage site, polynucleotide molecules encoding such toxins or chimeras, compositions comprising such toxins or chimeras, and method of producing such toxins or chimeras.
    Type: Application
    Filed: November 22, 2013
    Publication date: August 14, 2014
    Inventors: LANCE E. STEWARD, SANJIV GHANSHANI, ESTER FERNANDEZ-SALAS, MARCELLA A. GILMORE, JOSEPH FRANCIS, KEI ROGER AOKI
  • Degradable Clostridial Toxins
    Publication number: 20140220627
    Abstract: The specification discloses Clostridial toxins or Clostridial toxin chimeras comprising an inactivation cleavage site, polynucleotide molecules encoding such toxins or chimeras, compositions comprising such toxins or chimeras, and method of producing such toxins or chimeras.
    Type: Application
    Filed: November 22, 2013
    Publication date: August 7, 2014
    Inventors: LANCE E. STEWARD, SANJIV GHANSHANI, ESTER FERNANDEZ-SALAS, MARCELLA A. GILMORE, JOSEPH FRANCIS, KEI ROGER AOKI
  • Degradable Clostridial Toxins
    Publication number: 20140127783
    Abstract: The specification discloses Clostridial toxins or Clostridial toxin chimeras comprising an inactivation cleavage site, polynucleotide molecules encoding such toxins or chimeras, compositions comprising such toxins or chimeras, and method of producing such toxins or chimeras.
    Type: Application
    Filed: November 21, 2013
    Publication date: May 8, 2014
    Inventors: Lance E. Steward, Sanjiv Ghanshani, Ester Fernandez-Salas, Marcella A. Gilmore, Joseph Francis, Kei Roger Aoki
  • Degradable clostridial toxins
    Patent number: 8697413
    Abstract: The specification discloses Clostridial toxins or Clostridial toxin chimeras comprising an inactivation cleavage site, polynucleotide molecules encoding such toxins or chimeras, compositions comprising such toxins or chimeras, and method of producing such toxins or chimeras.
    Type: Grant
    Filed: August 16, 2013
    Date of Patent: April 15, 2014
    Assignee: Allergan, Inc.
    Inventors: Lance E. Steward, Sanjiv Ghanshani, Ester Fernandez-Salas, Marcella A. Gilmore, Joseph Francis, Kei Roger Aoki
  • Degradable clostridial toxins
    Patent number: 8697414
    Abstract: The specification discloses Clostridial toxins or Clostridial toxin chimeras comprising an inactivation cleavage site, polynucleotide molecules encoding such toxins or chimeras, compositions comprising such toxins or chimeras, and method of producing such toxins or chimeras.
    Type: Grant
    Filed: August 16, 2013
    Date of Patent: April 15, 2014
    Assignee: Allergan, Inc.
    Inventors: Lance E. Steward, Sanjiv Ghanshani, Ester Fernandez-Salas, Marcella A. Gilmore, Joseph Francis, Kei Roger Aoki
  • Degradable clostridial toxins
    Patent number: 8685692
    Abstract: The specification discloses Clostridial toxins or Clostridial toxin chimeras comprising an inactivation cleavage site, polynucleotide molecules encoding such toxins or chimeras, compositions comprising such toxins or chimeras, and method of producing such toxins or chimeras.
    Type: Grant
    Filed: March 18, 2013
    Date of Patent: April 1, 2014
    Assignee: Allergan, Inc.
    Inventors: Lance E. Steward, Sanjiv Ghanshani, Ester Fernandez-Salas, Marcella A. Gilmore, Joseph Francis, Kei Roger Aoki
  • Degradable clostridial toxins
    Patent number: 8685693
    Abstract: The specification discloses Clostridial toxins or Clostridial toxin chimeras comprising an inactivation cleavage site, polynucleotide molecules encoding such toxins or chimeras, compositions comprising such toxins or chimeras, and method of producing such toxins or chimeras.
    Type: Grant
    Filed: March 18, 2013
    Date of Patent: April 1, 2014
    Assignee: Allergan, Inc.
    Inventors: Lance E. Steward, Sanjiv Ghanshani, Ester Fernandez-Salas, Marcella A. Gilmore, Joseph Francis, Kei Roger Aoki
  • Modified Clostridial toxins with enhanced targeting capabilities for endogenous Clostridial toxin receptor systems
    Patent number: 8623999
    Abstract: The specification discloses modified Clostridial toxins comprising a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain and an enhanced Clostridial toxin binding domain; polynucleotide molecules encoding such modified Clostridial toxins; and method of producing such modified Clostridial toxins.
    Type: Grant
    Filed: February 27, 2012
    Date of Patent: January 7, 2014
    Assignee: Allergan, Inc.
    Inventors: Lance E. Steward, Ester Fernandez-Salas, Joseph Francis, Shengwen Li, Marcella A. Gilmore, Kei Roger Aoki
  • MODIFIED CLOSTRIDIAL TOXINS WITH ENHANCED TRANSLOCATION CAPABILITIY
    Publication number: 20130345413
    Abstract: The specification discloses modified Clostridial toxins comprising a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain, a translocation facilitating domain and an enhanced targeting domain; polynucleotide molecules encoding such modified Clostridial toxins; and method of producing such modified Clostridial toxins.
    Type: Application
    Filed: August 20, 2013
    Publication date: December 26, 2013
    Applicant: Allergan, Inc.
    Inventors: Lance E. Steward, Joseph Francis, Ester Fernandez-Salas, Marcella A. Gilmore, Shengwen Li
  • DEGRADABLE CLOSTRIDIAL TOXINS
    Publication number: 20130330806
    Abstract: The specification discloses Clostridial toxins or Clostridial toxin chimeras comprising an inactivation cleavage site, polynucleotide molecules encoding such toxins or chimeras, compositions comprising such toxins or chimeras, and method of producing such toxins or chimeras.
    Type: Application
    Filed: August 16, 2013
    Publication date: December 12, 2013
    Applicant: Allergan, Inc.
    Inventors: Lance E. Steward, Sanjiv Ghanshani, Ester Fernandez-Salas, Marcella A. Gilmore, Joseph Francis, Kei Roger Aoki
  • DEGRADABLE CLOSTRIDIAL TOXINS
    Publication number: 20130330807
    Abstract: The specification discloses Clostridial toxins or Clostridial toxin chimeras comprising an inactivation cleavage site, polynucleotide molecules encoding such toxins or chimeras, compositions comprising such toxins or chimeras, and method of producing such toxins or chimeras.
    Type: Application
    Filed: August 16, 2013
    Publication date: December 12, 2013
    Applicant: Allergan, Inc.
    Inventors: Lance E. Steward, Sanjiv Ghanshani, Ester Fernandez-Salas, Marcella A. Gilmore, Joseph Francis, Kei Roger Aoki
  • DEGRADABLE CLOSTRIDIAL TOXINS
    Publication number: 20130288334
    Abstract: The specification discloses Clostridial toxins or Clostridial toxin chimeras comprising an inactivation cleavage site, polynucleotide molecules encoding such toxins or chimeras, compositions comprising such toxins or chimeras, and method of producing such toxins or chimeras.
    Type: Application
    Filed: March 18, 2013
    Publication date: October 31, 2013
    Inventors: Lance E. Steward, Sanjiv Ghanshani, Ester Fernandez-Salas, Marcella A. Gilmore, Joseph Francis, Kei Roger Aoki
  • DEGRADABLE CLOSTRIDIAL TOXINS
    Publication number: 20130273633
    Abstract: The specification discloses Clostridial toxins or Clostridial toxin chimeras comprising an inactivation cleavage site, polynucleotide molecules encoding such toxins or chimeras, compositions comprising such toxins or chimeras, and method of producing such toxins or chimeras.
    Type: Application
    Filed: March 18, 2013
    Publication date: October 17, 2013
    Inventors: Lance E. Steward, Sanjiv Ghanshani, Ester Fernandez-Salas, Marcella A. Gilmore, Joseph Francis, Kei Roger Aoki